+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences

Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences

Developments in Biological Standardization 67: 311-317

Sterilization of human plasma with beta-propiolactone and UV-irradiation (cold sterilization) has been shown to be effective for a number of common pathogenic viruses. We have published data on the hepatitis safety of cold sterilized factor IX concentrates (PPSB) in healthy volunteers. This study has now been extended to include 6 virgin hemophilia B patients, who have been treated with cold sterilized PPSB for a period of up to 5 years. None of these volunteers or patients exhibited clinical symptoms or laboratory data indicating the transmission of either viral hepatitis (B or NANB) or acquired immunodeficiency syndrome (AIDS). Hyperimmunoglobulin (HIg) preparations from cold sterilized plasma, offering protection against hepatitis B and NANB are also safe regarding HTLV-III virus transmission, even though these preparations may contain HTLV-III antibody titers up to 1:1000.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 041957595

Download citation: RISBibTeXText

PMID: 3649316

Related references

A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin. Arzneimittel-Forschung 31(11): 1928-1930, 1981

Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thrombosis Research 28(1): 75-83, 1982

The safety of beta-propiolactone as a biologic sterilizing agent. Clinical evaluation with human plasma and homotransplants. Angiology 12: 80-83, 1961

Virus inactivation in human plasma and plasma fractions by means of beta propiolactone beta pl and beta pl uv. Stoltz, J F And C Rivat (Ed ) Colloque Inserm (Institut National De La Sante Et De La Recherche Medicale), Vol 175 Biotechnologie Des Proteines Du Plasma: Purification Et Utilisations Cliniques Et Biologiques; (Inserm (National Institute Of Health And Medical Research) Colloquium), Vol 175 Biotechnology Of Plasma Proteins: Fractionation And Applications; International Symposium, Nancy, France, May 17-19, 1988 Xii+501p Les Editions Inserm: Paris, France Illus Paper 391-398, 198, 1989

Safety of beta propiolactone uv treated ppsb factor ix concentrate. Thrombosis Research (Suppl. 7): 49, 1987

Inactivation of Aujeszkys virus by beta propiolactone and preparations of an oily vaccine for the immunization of dogs. Clinica veterinaria: 100 (7) 499-505, 1977

Hemostatic agents prepared from beta propiolactone uv treated plasma. Haemostasis 15(1): 12, 1985

Analysis of beta-propiolactone by gas chromatography. I. A residue of beta-propiolactone in rabies vaccine. II. Hydrolysis of beta-propiolactone at pH 7.4. Journal of Chromatography 70(1): 128-134, 1972

Immunogenicity of Newcastle disease virus preparations inactivated with beta-propiolactone, nitrosoguanidine, ethyl sulfate, or urethane. Avian Diseases 10: 83-88, 1966

Immunogenicity of the rabies virus treated with phenol, beta-propiolactone and heat. Veterinariia 1980(3): 32-33, 1980

Virucidal activity of beta-propiolactone vapor. I. Effect of beta-propiolactone vapor on Venezuelan equine encephalomyelitis virus. Applied Microbiology 7(4): 199-201, 1959

Experimental studies and clinical experiences with homologous tendon grafts preserved with beta-propiolactone. Handchirurgie 12(3-4): 207-211, 1980

Inactivation and antigenicity of poliomyelitis virus type 2 (MEF-1 strain) treated with beta-propiolactone. Rivista Dell'istituto Sieroterapico Italiano 31(1): 65-68, 1956

Serological response in chickens to beta-propiolactone treated Newcastle disease virus. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine 91(2): 288-290, 1956

Comparative tests of inactivation and antigenicity of the Newcastle virus treated with beta-propiolactone and with formol. Rivista Dell'istituto Sieroterapico Italiano 41(1): 11-21, 1966